COLLEGIUM PHARMACEUTICAL

Company snapshot

Collegium Pharmaceutical is building a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a portfolio of differentiated medications to treat serious medical conditions.

• 1 approved product(s) across US/EU regulatory metadata.
• 29 active pipeline program(s) linked via ClinicalTrials.gov.
• 28 US patent(s) indexed to this assignee profile.

Public regulatory, clinical, patent, and corporate records for COLLEGIUM PHARMACEUTICAL. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for COLLEGIUM PHARMACEUTICAL.

1. Jun 8, 2026 Clinical update

   DICES — Phase 3

2. Jun 8, 2026 Clinical update

   PREVENT-MINS — Phase 3

3. Jun 8, 2026 Clinical update

   PB_A&A-ASC-FISTULA_1 — Phase 3

4. Jun 8, 2026 Clinical update

   HYP-NOR — Phase 3

5. Jun 8, 2026 Clinical update

   CADET-PAD — Phase 3

View all clinical trial activity →

• What is COLLEGIUM PHARMACEUTICAL?

  Collegium Pharmaceutical is a pharma organization headquartered in Stoughton, USA. It trades on NYSE under ticker COLL. Primary therapeutic focus areas include Unstable Angina Pectoris, Gastric Carcinoma, aspirin-exacerbated respiratory disease, Ischemia of the lower limbs in the

• Is COLLEGIUM PHARMACEUTICAL publicly traded?

  Yes. COLLEGIUM PHARMACEUTICAL is listed with ticker COLL on NYSE per SEC EDGAR records linked on this profile.

• What drugs does COLLEGIUM PHARMACEUTICAL develop or market?

  We link 48 drug profile(s) where COLLEGIUM PHARMACEUTICAL is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/collegium-pharmaceutical-inc#company-drugs.

• What are the latest developments for COLLEGIUM PHARMACEUTICAL?

  In the last 12 months our linked public records show 29 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does COLLEGIUM PHARMACEUTICAL focus on?

  COLLEGIUM PHARMACEUTICAL focuses on Unstable Angina Pectoris, Gastric Carcinoma, aspirin-exacerbated respiratory disease based on our analysis of their pipeline programs and drug development activities.